Needham Reiterates Buy on Stoke Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a price target of $25.
August 07, 2023 | 6:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Stoke Therapeutics and maintained a price target of $25.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $25 price target indicates a positive outlook for Stoke Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100